| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| CD200 R1 | Human CD200 R1 / CRTR2 Protein, His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | ||
| CD200 R1 | Avitag CR2-H82F4 | Biotinylated Human CD200 R1 / CRTR2 Protein, Fc,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| High selective OX1R/OX2R dual inhibitor treating insomnia | Small molecule | Neurological disease | Insomnia | Phase I | Global |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| P-006 | 23ME-00610; P-006; 23ME’610 | Phase 2 Clinical | 23andme Inc | Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Microsatellite instability-high cancer; Neuroendocrine Tumors; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| GS-5305 | GS-5305 | Phase 1 Clinical | Gilead Sciences Lda | Inflammation | Details |
| DS-234 | DS-234; ARQ-234 | Phase 1 Clinical | Ducentis BioTherapeutics Ltd | Dermatitis, Atopic; Eczema | Details |
| Ucenprubart | LY-3454738 | Phase 1 Clinical | Eli Lilly And Company | Chronic Urticaria; Dermatitis, Atopic | Details |